Aurobindo Upbeat On Outlook, Transfers Biologics Biz
Seeks FDA Desk Reviews For Three Units
Executive Summary
After double-digit growth in formulation sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which is now transferred to its fully owned subsidiary for $48m.
You may also be interested in...
Aurobindo Expects Interim Phase II/III COVID-19 Vaccine Data By July
Aurobindo expects the first data readouts from the Phase II/III clinical trials of its partnered COVID-19 vaccine by July. While making progress in biosimilars development, the Indian company also plans to invest substantially in new API capacity.
Aurobindo's US Respiratory Filing Could Rival Teva's Qvar
Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, Aurobindo hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges. Meanwhile, building on assets acquired from Profectus BioSciences, the firm has thrown its hat in the ring for a COVID-19 vaccine.
Aurobindo Enters Fray For COVID-19 Vaccine
Building on assets acquired from Profectus BioSciences, Aurobindo Pharma has thrown its hat in the ring for a COVID-19 vaccine. Amid speculation it has filed for a generic to Teva’s asthma product Qvar in the US, the company hopes a healthy product pipeline will help it maintain growth despite pandemic-led challenges.